References
- Bruno G. A., Christian J. E. Determination of carbon-14 in aqueous bicarbonate solutions by liquid scintillation counting techniques. Analytical Chemistry 1961; 33: 1216–1218
- Clozel J. P, Fischli W. Comparative effects of different potent renin inhibitors in primates. Hypertension 1993; 22: 9–17
- Coassolo Ph., Fischli W., Clozel J. P, Chou R. C. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin in the rat, dog and primate. Xenobiotica 1996; 26: 333–346
- Do T. -S., Shinagawa T., Tam H., Inagami T., Hsueh W. A. Characterization of pure human renal renin—evidence for a subunit structure. Journal of Biological Chemistry 1987; 262: 1037–1043
- Erdös E. G. Angiotensin I converting enzyme. Circulation Research 1975; 36: 247–255
- Fischli W., Clozel J. -P., El Amrani K., Wostl W., Neidhart W., Stadlep H., Branca Q. Ro 42–5892 is a potent orally active renin inhibitor in primates. Hypertension 1991; 18: 22–31
- Fouad-Tarazi F., Bumpus M., Healy B. The renin-angiotensin system and treatment of heart failure. American Journal of Medicine 1988; 84(suppl. 3A)83–86
- Jauch R., Schmid P., Fischli W., Meister W., Maurer R., Wendt G. Excretion and metabolism of remikiren, a potent oral inhibitor of primate renin. Xenobiotica 1996; 26: 285–296
- Kobrin I., Viskoper R. J., Laszt A., Bock J., Weber C., Charlon V. Effects of an orally active renin inhibitor, Ro 42–5892, in patients with essential hypertension. American Journal of Hypertension 1993; 6: 349–356
- Kokubu T., Hiwada K. Human renin inhibitors. Drugs Today 1987; 23: 101–108
- Lindgren B. R., Andersson R. G. G. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. Medical Toxicology and Adverse Drug Experimentation 1989; 4: 369–380
- Rongen G. A., Lenders J. W. M., Kleinbloesem C. H., Weber C., Welker H., Fahrner E., Pozenel H., Woittiez A. -J. J., Haug G., Buchmann M. S., Höglund C. E. K., Thien T. Efficacy and tolerability of the renin inhibitor Ro 42–5892 in patients with hypertension. Clinical Pharmacology and Therapeutics 1993; 54: 567–577
- van den Meiracker A. H., Admiraal P. J. J., Man In't Feld A. J., Derkx F. H. M., Ritsema van Eck H. J., Mulder P., van Brummelen P., Schalekamp M. A. D.H. Prolonged blood pressure reduction by orally active renin inhibitor Ro 42–5892 in essential hypertension. British Medical Journal 1990; 301: 205–210
- Véniant M., Clozel J. -P., Hess P., Fischli W. Effects of renin-angiotensin system blockade in the guinea-pig. Hypertension 1992; 19: 255–262
- Viskoper R. J., Charlon V., Laszt A., Yosefy C., Bock J., Laudau M., Kobrin I. Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42–5892. Journal of Human Hypertension 1994; 8: 133–136